Anixa Biosciences to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
On March 2, 2023, Anixa Biosciences (NASDAQ: ANIX) announced that its CEO, Dr. Amit Kumar, will present a corporate update at the company’s 2023 Annual Meeting of Stockholders on March 9 at 10:00 AM PST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On March 2, 2023, Anixa Biosciences (NASDAQ: ANIX) announced that its CEO, Dr. Amit Kumar, will present a corporate update at the company’s 2023 Annual Meeting of Stockholders on March 9 at 10:00 AM PST. The meeting will be virtual and accessible to shareholders and other interested parties via this link. Anixa focuses on developing treatments for cancer and infectious diseases, with collaborations involving cutting-edge technologies in cancer immunotherapy and COVID-19 therapeutics. The company emphasizes its unique business model of partnering with renowned research institutions.
Positive
- Collaboration with Moffitt Cancer Center for innovative CAR-T therapies.
- Development of a COVID-19 therapeutic targeting the Mpro enzyme with MolGenie GmbH.
- Novel vaccines in collaboration with Cleveland Clinic for breast and ovarian cancer.
Negative
- None.
Details
News Market Reaction – ANIX
The recorded move for ANIX in the trading session of this news was -4.98%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Shareholders and all other interested parties may attend the meeting by going to www.virtualshareholdermeeting.com/ANIX2023.
About
Anixa is a clinical-stage biotechnology company with programs addressing cancer and infectious disease. Anixa's portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with
Contact:
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-provide-corporate-update-at-its-2023-annual-meeting-of-stockholders-301760537.html
SOURCE
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.